With multiple clinical stage product candidates in Phase 2 and Phase 3 development, each from a new class of potential intranasal therapies that we call pherines, each has a differentiated mechanism ...

With multiple clinical stage product candidates in Phase 2 and Phase 3 development, each from a new class of potential intranasal therapies that we call pherines, each has a differentiated mechanism ...

Needle-free, nasal delivery of adrenaline has the potential to become an important treatment option in anaphylaxis ALK also gains rights to future indications, including acute urticaria flares (in ...

The randomized, double-blind WAYPOINT trial tested Tezspire’s efficacy and safety in adults with severe CRSwNP who continued ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

Despite increased expenses and net loss, Vistagen Therapeutics Inc (VTGN) advances its neuroscience pipeline with promising ...

In the end it took a flip of the coin by the Denali Borough mayor to end a surprising tie in the childrens’ election ballot ...

A new therapy may delay Alzheimer’s disease progression by years, according to a study by researchers at Texas A&M University ...

Roxybond (oxycodone hydrochloride) immediate-release 10mg tablet for the management of pain severe enough to require an opioid analgesic.

Rather than bribing and wheedling physicians to pretty-please-prescribe-our-drug, websites allow companies to deal drugs ...

The combination of intranasal insulin (INI) and the sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin had ...

Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new ...